Clinical Trial: Role of Early API in Accurately Differentiating Hepatocellular Carcinoma From Dysplastic Nodules in Cirrhotic Patients

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080372) titled 'Role of Early API in Accurately Differentiating Hepatocellular Carcinoma From Dysplastic Nodules in Cirrhotic Patients' on June 28.

Brief Summary: Liver cirrhosis is a common consequence of chronic liver disease, resulting from sustained hepatic injury due to various etiologies. Cirrhosis predisposes individuals to the development of hepatocellular carcinoma (HCC), the most prevalent primary malignancy of the liver. Among cirrhotic patients, distinguishing between hepatocellular carcinoma and dysplastic nodules is crucial for timely diagnosis, treatment planning, and prognostic assessment.

Study Start Date: March 17

Study Type: OB...